Significant OS advantage was reported in the majority of subgroups in a stratified assessment of OS benefit, including hormone receptor status, menopausal status, the location and number of tumor metastases, age, race, line of disease therapy, and endocrine therapeutic agents. This evidence concerns the gene NR4A1 and neoplasm.